Tumor-associated exosome (TEX)

Tumor-associated exosomes are specialized extracellular vesicles, typically ranging from 30 to 150 nanometers in diameter, that are actively secreted by malignant cells into the surrounding microenvironment and systemic circulation (Source: Nature Reviews Cancer, 2012). These vesicles serve as critical mediators of intercellular communication by transporting a diverse cargo of bioactive molecules, including proteins, lipids, and various RNA species, from the tumor to both local and distant recipient cells (Source: Cell, 2018). In the context of oncology, they facilitate the remodeling of the tumor microenvironment, promote angiogenesis, and prepare pre-metastatic niches in distant organs, thereby driving cancer progression and metastasis (Source: Nature, 2015). Additionally, tumor-associated exosomes play a significant role in immune evasion by carrying ligands such as PD-L1 that suppress T-cell activity (Source: Nature, 2018). Therapeutic interventions targeting these vesicles include the inhibition of their biogenesis and secretion using small molecules like GW4869, the blockade of their uptake by recipient cells, and their physical removal from the blood using extracorporeal devices like the Aethlon Hemopurifier (Source: Journal of Extracellular Vesicles, 2020).

Other names

Tumor-derived exosomeCancer-derived exosomeMalignant exosomeTumor-derived extracellular vesicleOncosome

Inhibition of exosome biogenesis (e.g., via neutral sphingomyelinase inhibition), inhibition of exosome secretion/release, blockade of exosome uptake by recipient cells (e.g., via heparan sulfate proteoglycan competition), and physical extracorporeal removal from circulation.